混合18F-FDG PET/MRI可能改善乳腺癌患者新辅助化疗前的局部区域分期
这项前瞻性研究纳入40例接受新辅助化疗的原发性浸润性cT2-4 N0或cT1-4 N+乳腺癌患者,在治疗前进行PET/MRI乳腺协议检查,并与传统影像(乳腺X线摄影、超声和MRI)比较局部区域分期。PET/MRI在20.0%(8/40)患者中具有附加临床价值,其中10%改变了治疗方案,另10%确认了MRI可疑病灶的恶性性质。
要点
- PET/MRI在20.0%(8/40)患者中具有附加临床价值。
- 10%患者基于PET/MRI发现改变了治疗方案。
- 7例(17.5%)放疗野扩大,1例(2.5%)放疗野缩小。
核心结论
- 新辅助化疗前,PET/MRI与传统影像相比在局部区域分期方面显示出有希望的结果,10%患者治疗方案改变,另10%患者可能替代PET/CT或组织取样。
研究设计与样本
- 前瞻性研究纳入40例接受新辅助化疗的原发性浸润性cT2-4 N0或cT1-4 N+乳腺癌患者,治疗前进行PET/MRI乳腺协议检查并比较传统影像。
主要发现
- PET/MRI在20.0%(8/40)患者中具有附加临床价值,其中10%改变治疗方案,另10%确认MRI可疑病灶的恶性性质。
- 7例(17.5%)患者因PET/MRI额外或确认的淋巴结转移(n=5)和胸骨骨转移(n=2)而扩大放疗野。
- 1例(2.5%)患者因PET/MRI显示淋巴结转移少于传统影像而缩小放疗野。
- 所有治疗改变均基于可疑转移淋巴结数目或远处转移数目的差异,未观察到乳腺内肿瘤范围差异。
临床怎么用
- 新辅助化疗前PET/MRI在局部区域分期方面显示出有希望的结果,可改变10%患者的治疗方案,并可能在另10%患者中替代PET/CT或组织取样。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose in this study was to assess the added clinical value of hybrid 18F-FDG-PET/MRI compared to conventional imaging for locoregional staging in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). METHODS: In this prospective study, primary invasive cT2-4 N0 or cT1-4 N+ breast cancer patients undergoing NAC were included. A PET/MRI breast protocol was performed before treatment. MR images were evaluated by a breast radiologist, blinded for PET images. PET images were evaluated by a nuclear physician. Afterwards, a combined PET/MRI report was written. PET/MRI staging was compared to conventional imaging, i.e., mammography, ultrasound and MRI. The proportion of patients with a modified treatment plan based on PET/MRI findings was analyzed. RESULTS: A total of 40 patients was included. PET/MRI was of added clinical value in 20.0% (8/40) of patients, changing the treatment plan in 10% and confirming the malignancy of suspicious lesions on MRI in another 10%. In seven (17.5%) patients radiotherapy fields were extended because of additional or affirmative PET/MRI findings being lymph node metastases (n = 5) and sternal bone metastases (n = 2). In one (2.5%) patient radiotherapy fields were reduced because of fewer lymph node metastases on PET/MRI compared to conventional imaging. Interestingly, all treatment changes were based on differences in number of lymph nodes suspicious for metastasis or number of distant metastasis, whereas differences in intramammary tumor extent were not observed. CONCLUSION: Prior to NAC, PET/MRI shows promising results for locoregional staging compared to conventional imaging, changing the treatment plan in 10% of patients and potentially replacing PET/CT or tissue sampling in another 10% of patients.
引用
- Goorts B, Vöö S, van Nijnatten TJA, et al. Hybrid 18F-FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2017. PMID: 28600647. doi:10.1007/s00259-017-3745-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。